We compared results of chromatic pupillometry testing in 37 dogs with different stages of primary loss of rod, cone, combined rod/cone, and optic nerve functions with those in 5 wild-type (WT) dogs (
Table). Diseases included
CNGB1-progressive retinal atrophy (PRA),
CNGB3 achromatopsia (ACHM),
PDE6B rod/cone dysplasia 1 (rcd1),
RD3 rod/cone dysplasia 2 (rcd2),
PDE6A rod/cone dysplasia 3 (rcd3),
RPE65 Leber congenital amaurosis (LCA),
PRCD progressive rod/cone degeneration (prcd),
IQCB1 cone/rod dystrophy 2 (crd2),
RPGR-X-linked progressive retinal atrophy 2 (XLPRA2),
STK38L early retinal degeneration (erd), and
NEHJ1 Collie eye anomaly (CEA).
16–39 Dogs were grouped and tested based on 4 previously reported retinal and optic nerve disease phenotypes, as follows: (1) Group 1 consisted of primary loss of rod function in dogs with
CNGB1-PRA and young (<1 year of age) dogs with
PDE6A-rcd3 and
PDE6B-rcd1; (2) group 2 included primary loss of cone function in dogs with
CNGB3-ACHM; (3) group 3 contained various severities of combined loss of rod and cone function in older dogs affected with
PDE6B-rcd1,
RD3-rcd2, and
PDE6A-rcd3, and dogs affected with
RPE65-LCA,
PRCD-prcd,
IQCB1-crd2,
STK38L-erd, and
RPGR-XLPRA2; (4) and group 4 included primary loss of optic nerve function in 1 dog with severe optic nerve head coloboma due to
NEHJ1-CEA, which was also affected by
RD3-rcd2. We also assessed pupillary responses to differential blue and red light intensities in 2 additional WT and 2
CNGB3-mutant dogs.